Search
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexDiphenidol
go.drugbank.com/drugs/DB01231ApprovedWithdrawnDiphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigationalAnthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. … It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium.
Goserelin
go.drugbank.com/drugs/DB00014ApprovedInvestigationalGoserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. … In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state.
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalA compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. … As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Synonyms: Actinomycin D, ACTINOMYCIN-DCategories: P-glycoprotein substrates with a Narrow Therapeutic IndexChloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approvedChloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. … [A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].
Melatonin
go.drugbank.com/drugs/DB01065ApprovedInvestigationalNutraceuticalVet approvedThe pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus … A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme
Categories: Compounds used in a research, industrial, or household settingRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalOriginally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pivoted toward oncology as a potent sensitizing … in the context of resistant cancers.
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.